Literature DB >> 6896223

Effects of calcitriol administration on calcium metabolism healthy men.

N D Adams, R W Gray, J Lemann, H S Cheung.   

Abstract

To evaluate the relationship between daily and fasting urinary calcium excretion and serum 1,25-(OH)2-D concentrations, we studied six healthy men during control and during chronic oral calcitriol administration (0.6, 1.2, or 1.8 nmoles every 6 hours for 6 to 12 days) while they ate normal and low calcium diets (calcium content, 19.2 or 4.2 mmoles/day). Daily urinary calcium excretion was directly related to serum 1,25-(OH)2-D concentrations but increased more (P less than 0.025) while subjects ate the normal calcium diet (slope, 0.081 mmole/day/pmole/liter, r = 0.94) than when eating the low calcium diet (slope, 0.043 mmole/day/pmole/liter; r=0.83). During calcitriol and ingestion of the low calcium diet, daily urinary calcium excretion averaged 7.32 +/- 2.6 mmoles/day, exceeding the dietary calcium intake (P less than 0.02). Moreover, during calcitriol, when serum 1,25-(OH)2-D exceeded 140 pmoles/liter, fasting urinary calcium/creatinine exceeded 0.34 mmole/mmole (the upper limit of normal) on either diet. When serum 1,25-(OH)2-D concentrations are elevated, a high fasting urinary calcium/creatinine or high daily urinary calcium excretion, even on a low calcium diet, is insufficient criteria for the documentation of a renal calcium leak.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896223     DOI: 10.1038/ki.1982.13

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Bone disease in pediatric idiopathic hypercalciuria.

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  World J Nephrol       Date:  2012-04-06

2.  Rare Occurrence of 3 "H": Hypercalcemia, Hemolytic Anemia and Hodgkin's Lymphoma.

Authors:  Ankur Jain; Pankaj Malhotra; Gaurav Prakash; Subhash Varma; Narender Kumar; Asim Das
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-23       Impact factor: 0.900

3.  Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Authors:  Eric N Taylor; Andrew N Hoofnagle; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-26       Impact factor: 8.237

4.  1,25(OH)₂D₃ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats.

Authors:  Adeline H Ng; Kevin K Frick; Nancy S Krieger; John R Asplin; Madison Cohen-McFarlane; Christopher D Culbertson; Kelly Kyker-Snowman; Marc D Grynpas; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2014-01-31       Impact factor: 4.333

5.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

Review 6.  New insights into the pathogenesis of idiopathic hypercalciuria.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

7.  Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Authors:  Kevin K Frick; John R Asplin; Murray J Favus; Christopher Culbertson; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-23

8.  Pathophysiology of spontaneous hypercalciuria in laboratory rats. Role of deranged vitamin D metabolism.

Authors:  K Lau; D Thomas; C Langman; B Eby
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  The hormonal form of vitamin D in the pathophysiology and therapy of postmenopausal osteoporosis.

Authors:  A Caniggia; R Nuti; F Loré; A Vattimo
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

Review 10.  Modeling hypercalciuria in the genetic hypercalciuric stone-forming rat.

Authors:  Kevin K Frick; Nancy S Krieger; David A Bushinsky
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.